Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

Summary

The purpose of this research study is to evaluate the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by inhalation (breathed into the lungs) three times a week for 12 weeks. The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is the condition being examined in this study.

Timeline

Start

2001-02

Primary completion

—

Completion

2002-10

Drugs

Indications